Interim results from a phase 1 study of molibresib, another BET inhibitor tested in patients with NHL [63, 80], found that 70% of participants (n/N = 19/27) experienced grade ≥ 3 thrombocytopenia [80]. This evidence concerns the gene DNER and Thrombocytopenia.